JP5806112B2 - デング出血熱およびデングショック症候群を含む免疫介在性デング熱感染症およびデング熱感染症の抗体依存性増強を処置するための方法 - Google Patents

デング出血熱およびデングショック症候群を含む免疫介在性デング熱感染症およびデング熱感染症の抗体依存性増強を処置するための方法 Download PDF

Info

Publication number
JP5806112B2
JP5806112B2 JP2011518930A JP2011518930A JP5806112B2 JP 5806112 B2 JP5806112 B2 JP 5806112B2 JP 2011518930 A JP2011518930 A JP 2011518930A JP 2011518930 A JP2011518930 A JP 2011518930A JP 5806112 B2 JP5806112 B2 JP 5806112B2
Authority
JP
Japan
Prior art keywords
denv
polypeptide
binding
dengue
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011518930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528665A (ja
JP2011528665A5 (enExample
Inventor
ネイル エム． ボディー
ネイル エム． ボディー
Original Assignee
トリニティー セラピューティクス インコーポレイテッド
トリニティー セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トリニティー セラピューティクス インコーポレイテッド, トリニティー セラピューティクス インコーポレイテッド filed Critical トリニティー セラピューティクス インコーポレイテッド
Publication of JP2011528665A publication Critical patent/JP2011528665A/ja
Publication of JP2011528665A5 publication Critical patent/JP2011528665A5/ja
Application granted granted Critical
Publication of JP5806112B2 publication Critical patent/JP5806112B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011518930A 2008-07-18 2009-07-17 デング出血熱およびデングショック症候群を含む免疫介在性デング熱感染症およびデング熱感染症の抗体依存性増強を処置するための方法 Expired - Fee Related JP5806112B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8194308P 2008-07-18 2008-07-18
US61/081,943 2008-07-18
PCT/US2009/050966 WO2010009380A2 (en) 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Publications (3)

Publication Number Publication Date
JP2011528665A JP2011528665A (ja) 2011-11-24
JP2011528665A5 JP2011528665A5 (enExample) 2012-09-13
JP5806112B2 true JP5806112B2 (ja) 2015-11-10

Family

ID=41551029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011518930A Expired - Fee Related JP5806112B2 (ja) 2008-07-18 2009-07-17 デング出血熱およびデングショック症候群を含む免疫介在性デング熱感染症およびデング熱感染症の抗体依存性増強を処置するための方法

Country Status (13)

Country Link
US (1) US8815813B2 (enExample)
EP (1) EP2320924B1 (enExample)
JP (1) JP5806112B2 (enExample)
CN (1) CN102159231B (enExample)
AU (2) AU2009270805B2 (enExample)
BR (1) BRPI0915968B1 (enExample)
CA (1) CA2731218A1 (enExample)
HR (1) HRP20150620T1 (enExample)
IL (1) IL210717A (enExample)
MX (1) MX2011000647A (enExample)
MY (1) MY160699A (enExample)
SG (1) SG10201500597YA (enExample)
WO (1) WO2010009380A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005221187B2 (en) 2004-03-10 2011-09-01 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
CN102159231B (zh) 2008-07-18 2016-06-15 三一治疗公司 治疗免疫介导的登革热感染和登革热感染(包括登革出血热和登革休克综合征)的抗体依赖性增强作用的方法
US20170360875A1 (en) * 2014-12-22 2017-12-21 Middle Tennessee State University Methods for treating immune-mediated viral infections
JP6872181B2 (ja) * 2015-05-20 2021-05-19 国立大学法人 鹿児島大学 ＩｇＧ結合ペプチドによる抗体の特異的修飾
WO2017189891A1 (en) * 2016-04-27 2017-11-02 Middle Tennessee State University Methods for treating zika viral infections and associated complications
DK3470418T3 (da) 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
CN115804362A (zh) * 2023-02-08 2023-03-17 中国医学科学院医学生物学研究所 一种IFN-α/βR-/-小鼠抗体依赖性增强感染的注射液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4383317A (en) 1980-10-30 1983-05-10 Bei Electronics, Inc. Shaft angle encoder having a circuit for synthesizing a skipped track output signal
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5693758A (en) 1987-11-19 1997-12-02 501 Research Corporation Limited Immunoglobulin E competitor
US5932483A (en) 1990-10-16 1999-08-03 Northwestern University Synthetic peptide and its uses
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
ITMI962628A1 (it) 1996-12-16 1998-06-16 Tecnogen Scpa Composizione farmaceutica
CN1189166C (zh) 1998-09-11 2005-02-16 伊来克萨斯独资有限公司 Fc受体调节剂及其应用
JP2002534059A (ja) 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション，インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1332158B1 (de) 2000-11-08 2007-08-01 Fresenius Medical Care Affina GmbH Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6916904B2 (en) 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
DE60318065T2 (de) 2002-06-07 2008-11-20 Trillium Therapeutics Inc., Toronto Fcyriia-transgenes tiermodell für autoimmunkrankheit
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
AU2005221187B2 (en) * 2004-03-10 2011-09-01 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
AU2005272598B2 (en) 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US20080187490A1 (en) 2005-09-06 2008-08-07 Bodie Neil M Methods for Treating Amyotrophic Lateral Sclerosis
ES2359218T3 (es) 2005-12-13 2011-05-19 Suppremol Gmbh POLIPÉPTIDOS Y POLIMÉRICOS PARA LOS RECEPTORES Fc.
US20120021988A1 (en) 2007-08-14 2012-01-26 Bodie Neil M Methods for treating immune thrombocytopenia
CN102159231B (zh) 2008-07-18 2016-06-15 三一治疗公司 治疗免疫介导的登革热感染和登革热感染(包括登革出血热和登革休克综合征)的抗体依赖性增强作用的方法

Also Published As

Publication number Publication date
IL210717A0 (en) 2011-03-31
CN102159231A (zh) 2011-08-17
IL210717A (en) 2017-07-31
US8815813B2 (en) 2014-08-26
BRPI0915968B1 (pt) 2021-11-23
WO2010009380A9 (en) 2010-04-08
JP2011528665A (ja) 2011-11-24
HRP20150620T1 (xx) 2015-09-25
HK1158066A1 (en) 2012-07-13
US20110218157A1 (en) 2011-09-08
SG10201500597YA (en) 2015-04-29
EP2320924A4 (en) 2012-07-25
WO2010009380A2 (en) 2010-01-21
MX2011000647A (es) 2011-09-29
CA2731218A1 (en) 2010-01-21
AU2017200760A1 (en) 2017-03-02
EP2320924B1 (en) 2015-03-11
MY160699A (en) 2017-03-15
EP2320924A1 (en) 2011-05-18
AU2009270805B2 (en) 2016-11-03
CN102159231B (zh) 2016-06-15
BRPI0915968A2 (pt) 2020-08-18
AU2009270805A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
AU2017200760A1 (en) Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
US10179803B2 (en) Methods for inhibiting immune complex formation in a subject
US6916904B2 (en) Inhibition of immune complex formation
JP5329961B2 (ja) 免疫介在性神経疾患を治療するための方法
WO2017189891A1 (en) Methods for treating zika viral infections and associated complications
US20120021988A1 (en) Methods for treating immune thrombocytopenia
AU2011253771B2 (en) Method for inhibiting immune complex formation in a subject
HK1158066B (en) A polypeptide for use in treating dengue virus infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141222

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150903

R150 Certificate of patent or registration of utility model

Ref document number: 5806112

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees